com_NN Therapy_NNP area_NN review_NN sales_NNS and_CC further_JJ development_NN of_IN Nexium_NNP ._.
Cardiovascular_NNP CV_NNP We_PRP are_VBP a_DT world_NN leader_NN in_IN cardiovascular_JJ 40_CD %_NN of_IN adults_NNS in_IN the_DT western_JJ world_NN regularly_RB medicines_NNS ,_, with_IN over_IN 40_CD years_NNS experience_NN experience_NN heartburn_NN and_CC between_IN 10_CD and_CC and_CC a_DT powerful_JJ range_NN of_IN products_NNS ._.
Backed_NNP 20_CD %_NN have_VBP gastro-oesophageal_JJ reflux_NN by_IN our_PRP$ quality_NN research_NN ,_, we_PRP aim_VBP to_TO build_VB disease_NN GERD_NNP ._.
The_DT prevalence_NN of_IN GERD_NNP on_IN our_PRP$ strong_JJ position_NN ,_, focusing_VBG on_IN in_IN Asia_NNP is_VBZ lower_JJR ,_, but_CC increasing_VBG ._.
important_JJ areas_NNS of_IN need_NN such_JJ as_IN hypertension_NN ,_, diabetes_NN ,_, dyslipidemia_NN Nexium_NNP continues_VBZ to_TO establish_VB a_DT new_JJ and_CC thrombosis_NN ._.
improved_VBN treatment_NN standard_NN and_CC this_DT was_VBD reflected_VBN in_IN its_PRP$ global_JJ sales_NNS ,_, which_WDT CV_NNP disease_NN accounts_NNS for_IN 17_CD million_CD exceeded_VBD $_$ 3.8_CD billion_CD in_IN 2004_CD ._.
First_NNP deaths_NNS worldwide_JJ each_DT year_NN ,_, making_VBG it_PRP launched_VBD in_IN Sweden_NNP in_IN August_NNP 2000_CD ,_, the_DT greatest_JJS risk_NN to_TO life_NN for_IN most_JJS adults_NNS ._.
it_PRP is_VBZ now_RB available_JJ in_IN approximately_RB 100_CD markets_NNS ,_, including_VBG the_DT US_NNP ,_, Canada_NNP and_CC Crestor_NNP ,_, our_PRP$ new_JJ statin_NN for_IN controlling_VBG all_DT European_JJ countries_NNS ._.
It_PRP has_VBZ been_VBN well_RB cholesterol_NN levels_NNS ,_, is_VBZ now_RB approved_VBN in_IN 67_CD received_VBN by_IN patients_NNS and_CC physicians_NNS alike_RB markets_NNS and_CC launched_VBN in_IN 56_CD ,_, including_VBG the_DT and_CC close_VB to_TO 250_CD million_CD patient_JJ treatments_NNS US_NNP ,_, Canada_NNP and_CC the_DT majority_NN of_IN EU_NNP countries_NNS ._.
had_VBD been_VBN administered_VBN by_IN the_DT end_NN of_IN By_IN the_DT end_NN of_IN 2004_CD ,_, over_IN 15_CD million_CD 2004_CD ._.
Its_PRP$ strong_JJ performance_NN in_IN the_DT US_NNP prescriptions_NNS had_VBD been_VBN written_VBN for_IN ,_, and_CC over_IN makes_VBZ Nexium_NNP the_DT most_RBS successful_JJ four_CD million_CD patients_NNS treated_VBN with_IN Crestor_NNP ._.
Public_NNP Citizen_NNP ,_, a_DT US_NNP consumer_NN interest_NN organization_NN ,_, continued_VBD to_TO raise_VB allegations_NNS An_DT injectable_JJ intravenous_JJ formulation_NN concerning_VBG the_DT safety_NN of_IN Crestor_NNP ._.
of_IN Nexium_NNP is_VBZ now_RB approved_VBN in_IN 47_CD Clinical_JJ trials_NNS experience_NN and_CC post-marketing_JJ countries_NNS ,_, for_IN use_NN when_WRB an_DT oral_JJ treatment_NN surveillance_NN continue_VBP to_TO support_VB our_PRP$ belief_NN of_IN GERD_NNP is_VBZ not_RB appropriate_JJ ._.
In_IN September_NNP that_WDT Crestor_NNP has_VBZ a_DT safety_NN profile_NN in_IN line_NN with_IN 2004_CD ,_, approval_NN was_VBD granted_VBN through_IN the_DT other_JJ marketed_VBN statins_NNS ._.
Clinical_JJ trial_NN and_CC postEU_NNP Mutual_NNP Recognition_NNP Procedure_NNP for_IN the_DT marketing_NN data_NNS for_IN Crestor_NNP are_VBP publicly_RB use_NN of_IN Nexium_NNP in_IN the_DT healing_NN and_CC available_JJ on_IN a_DT dedicated_JJ website_NN ,_, prevention_NN of_IN ulcers_NNS associated_VBN with_IN ._.
com_NN ,_, which_WDT we_PRP non-steroidal_JJ anti-inflammatory_JJ launched_VBN in_IN September_NNP 2004_CD ._.
drug_NN NSAID_NNP therapy_NN ._.
Approval_NN for_IN the_DT reduction_NN in_IN occurrence_NN of_IN gastric_JJ ulcers_NNS 2004_CD saw_VBD the_DT first_JJ launches_NNS of_IN Exanta_NNP ,_, associated_VBN with_IN continuous_JJ NSAID_NNP our_PRP$ new_JJ oral_JJ anti-coagulant_JJ ,_, for_IN use_NN therapy_NN in_IN patients_NNS at_IN risk_NN for_IN developing_VBG in_IN preventing_VBG blood_NN clots_NNS following_VBG gastric_JJ ulcers_NNS was_VBD granted_VBN in_IN the_DT US_NNP orthopaedic_NN surgery_NN in_IN 10_CD countries_NNS ._.
In_IN October_NNP 2004_CD ,_, the_DT FDA_NNP confirmed_VBD that_IN it_PRP did_VBD not_RB approve_VB Exanta_NNP for_IN Infection_NNP marketing_NN in_IN the_DT US_NNP for_IN any_DT of_IN the_DT World_NNP demand_NN for_IN antibiotics_NNS remains_VBZ indications_NNS sought_VBD ._.
Discussions_NNS are_VBP high_JJ due_JJ to_TO escalating_VBG resistance_NN and_CC ongoing_JJ with_IN the_DT FDA_NNP to_TO determine_VB the_DT increased_VBN risk_NN of_IN serious_JJ infections_NNS ._.
whether_IN there_EX is_VBZ now_RB a_DT realistic_JJ prospect_NN Infectious_JJ diseases_NNS cause_VBP more_JJR than_IN of_IN bringing_VBG Exanta_NNP to_TO the_DT US_NNP market_NN ._.
At_IN the_DT end_NN of_IN 2004_CD ,_, we_PRP received_VBD approval_NN 2004_CD again_RB saw_VBD steady_JJ sales_NNS growth_NN in_IN the_DT EU_NNP ,_, and_CC an_DT approvable_JJ letter_NN from_IN globally_RB for_IN Merrem_NNP ,_, our_PRP$ antibiotic_JJ for_IN the_DT the_DT FDA_NNP ,_, for_IN the_DT use_NN of_IN Atacand_NNP in_IN heart_NN treatment_NN of_IN serious_JJ ,_, hospital-acquired_JJ failure_NN ,_, based_VBN on_IN the_DT results_NNS of_IN a_DT infections_NNS ._.
A_DT Supplementary_NNP New_NNP Drug_NNP comprehensive_JJ clinical_JJ study_NN program_NN ,_, Application_NN was_VBD filed_VBN in_IN the_DT US_NNP in_IN 2004_CD CHARM_NNP ,_, which_WDT showed_VBD significant_JJ aimed_VBN at_IN securing_VBG an_DT indication_NN for_IN skin_NN reduction_NN in_IN the_DT number_NN of_IN deaths_NNS and_CC and_CC skin_NN structure_NN infections_NNS in_IN 2005_CD ._.
hospitalisations_NNS for_IN heart_NN failure_NN in_IN patients_NNS treated_VBN with_IN Atacand_NNP ._.
Work_NN continues_VBZ at_IN our_PRP$ research_NN facility_NN in_IN Bangalore_NNP ,_, India_NNP where_WRB we_PRP are_VBP focused_VBN With_IN sales_NNS again_RB exceeding_VBG $_$ 1_CD billion_CD on_IN finding_VBG a_DT new_JJ treatment_NN for_IN tuberculosis_NN in_IN 2004_CD ,_, Seloken_NNP Toprol-XL_NNP is_VBZ the_DT worlds_NNS TB_NN ,_, the_DT single_JJ largest_JJS cause_NN of_IN adult_NN leading_VBG product_NN by_IN sales_NNS in_IN the_DT beta_JJ death_NN from_IN infectious_JJ disease_NN in_IN the_DT world_NN ._.
blocker_NN plain_NN and_CC in_IN combination_NN with_IN diuretic_JJ class_NN ._.
Neuroscience_NNP We_PRP aim_VBP to_TO deliver_VB a_DT range_NN of_IN life-changing_JJ Gastrointestinal_NNP GI_NNP medicines_NNS in_IN three_CD key_JJ areas_NNS of_IN psychiatry_NN ,_, We_PRP aim_VBP to_TO maintain_VB our_PRP$ number_NN one_CD position_NN analgesia_NN and_CC neurology_NN ,_, and_CC by_IN maintaining_VBG in_IN GI_NNP treatments_NNS through_IN driving_VBG continued_VBN our_PRP$ world_NN leading_VBG position_NN in_IN anaesthesia_NN ._.
